Join the 'Emverm' group to help and get support from people like you.
Posted 18 Jan 2016 by Drugs.com
HAYWARD, Calif., Jan. 15, 2016 /PRNewswire/ – Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the United States Food and Drug Administration (FDA) has approved the Company's supplemental new drug application (sNDA) for Emverm (mebendazole) 100 mg chewable tablets. Emverm is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Pinworm is a highly contagious parasite that infects approximately 40 million people in the United States each year.1 Pinworm infection is three times more common than head lice.2 Emverm is not for persons who have shown hypersensitivity to the drug. "We are pleased to announce the approval of Emverm, a new prescription product for the treatment of pinworm ... Read more
Related support groups: Pinworm Infection (Enterobius vermicularis), Worms, Mebendazole, Hookworm Infection (Necator or Ancylostoma), Ascariasis, Whipworm Infection, Pinworm Medicine, Emverm, Worms and Flukes